TMCnet News
CompanionDx Reference Lab, LLC and RegenWell Holdings, LLC Partner to Provide World-class Care to PatientsHOUSTON --(Business Wire)-- CompanionDx Reference Lab, a high-complexity CLIA certified laboratory specializing in pharmacogenomics, cancer companion diagnostics, targeted next generation sequencing (NGS) and epigenomics testing, is proud to join forces with RegenWell Holdings, a Georgia-based integrated healthcare provider. The partnership will bring CompanionDx Lab's personalized medicine and precision therapy genomic testing to the point of care to deliver reduced healthcare costs and improved patient outcomes by optimizing drug selection and dosing based on the genetic makeup of each individual patient. "RegenWell physician and healthcare provider clients will have an opportunity to further the utilization of genomic testing in the multi-specialty setting. We are eager about the opportunity to provide CompanionDx Lab's robust diagnostic testing protocols and comprehensive clinical reports to our partner healthcare organizations," said Dr. Michael Carter, CEO and CMO of RegenWell. "The alliance will bring quality healthcare and an improved quality of life to patients around the world." "This partnership is indicative of the trend in healthcare to create synergistic relationships which enable better healthcare options for patients," said Nikko Khazana, senior vice president o sales for CompanionDx Lab. "Through the CompanionDx Lab and RegenWell alliance, we are expanding the opportunity to use personal genomic information in patient care and therapeutic decision-making." "RegenWell's goal is to augment CompanionDx Lab's comprehensive clinical team-comprised of genetic counselors, PharmDs and PhDs-who provide actionable guidance into patient treatment protocols," said George Hawthorne, COO of RegenWell. "No other company is doing what CompanionDx Lab is doing in partnering with diverse health systems and physician groups to provide the next-generation of diagnostic tools for personalized treatment protocols enabling providers to make clinical decisions that improved therapeutic outcomes prior to initiation of therapy." About CompanionDxTM Lab With locations in Houston, Texas and Honolulu, Hawaii, CompanionDx Reference Lab is a high-complexity CLIA certified laboratory specializing in pharmacogenomics, cancer companion diagnostics, targeted NGS and epigenomics testing. CompanionDx Lab is committed to the next evolution in cancer care where comprehensive genetic data is delivered in an actionable format, thereby enabling the physician to make treatment decisions and choose healthcare strategies based on unique cancer type and the genetic makeup of each patient. CompanionDx Lab's comprehensive and tumor-specific panels, coupled with personalized pharmacogenomic analysis, provide a unique offering that allows physicians to choose relevant and targeted therapies. For more information, visit www.companiondxlab.com. About RegenWell Holdings, LLC RegenWell Holdings LLC and its operating subsidiaries are an integrated healthcare delivery system consisting of a network of healthcare organizations that provides a continuum of care in healthcare services under a parent holding company. The RegenWell Holdings LLC's "continuum of care" refers to a collaborative range of services within the healthcare sector that addresses chronic disease management, health and wellness needs. The RegenWell Holdings LLC's concept is based upon increasing intensity of care rather than a specific and unvarying list of services. Our operating subsidiary, RegenWell Health Solutions, works collaboratively with RegenWell Holdings LLC and its operating subsidiaries to optimize product/service performance to exceed expectations for product/service reliability, effectiveness, costs and availability. RegenWell Health Solutions' breadth of healthcare products and services-combined with global sales capabilities-provides healthcare providers, patients and organizations with integrated health delivery solutions from RegenWell Holdings LLC. |
